Pyrotinib After Trastuzumab-based Adjuvant Therapy in Patients With HER2-positive Breast Cancer

Summary

This trial is a multicenter, open-label, phase II trial conducted at 23 centers in China. High-risk HER2 positive patients receive pyrotinib 400mg/day for one year or half year for extented adjuvant therapy.

Timeline

Start

2019-01-01

Primary completion

2024-12-31

Completion

2025-12-31

Publications

• Cao F, Ma Z, Wu Z, Wu W, Wang O, Cui B, Zhu X, Hao J, Ji X, Li Z, Tao D, Feng Q, Lin W, Shi D, Shu J, Zhou J, Huang S. Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (PERSIST): A multicenter phase II trial. Elife. 2025 Apr 3;13:RP101724. doi: 10.7554/eLife.101724.

Drugs

Indications